The best indicator for West Pharmaceutical Services (WST)
We backtested 20 indicators across daily, weekly and hourly charts on real West Pharmaceutical Services (WST) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
RSI Trend (>50)
On the weekly chart, this is the strongest risk-adjusted edge we found for West Pharmaceutical Services (WST) over ~46.4 years — trailing buy-and-hold by 4.2% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | RSI Trend (>50) ✓ | Weekly | 11.1% | 0.59 | -49.0% | 56.1% | 107 | -4.2% |
| 2 | Donchian Midline ✓ | Weekly | 11.1% | 0.59 | -55.8% | 48.1% | 108 | -4.2% |
| 3 | SMA 50/200 Cross ✓ | Daily | 10.0% | 0.55 | -61.4% | 62.1% | 29 | -5.3% |
| 4 | RSI Trend (>50) ✓ | Daily | 9.6% | 0.55 | -52.7% | 38.3% | 582 | -5.7% |
| 5 | EMA-10 Trend ✓ | Weekly | 9.9% | 0.55 | -52.0% | 55.0% | 200 | -5.4% |
| 6 | Donchian Breakout ✓ | Daily | 8.0% | 0.52 | -45.9% | 50.0% | 192 | -7.3% |
| 7 | EMA 20/50 Cross ✓ | Daily | 9.1% | 0.5 | -55.9% | 43.0% | 100 | -6.3% |
| 8 | Rate of Change ✓ | Weekly | 8.7% | 0.5 | -59.5% | 51.1% | 131 | -6.6% |
| 9 | EMA 50/200 Cross ✓ | Daily | 8.6% | 0.48 | -65.3% | 51.7% | 29 | -6.7% |
| 10 | ADX / DMI ✓ | Daily | 7.1% | 0.48 | -52.5% | 41.9% | 313 | -8.2% |
| 11 | EMA 20/50 Cross ✓ | Weekly | 8.8% | 0.48 | -54.7% | 50.0% | 20 | -6.6% |
| 12 | WaveTrend (8/6/4) ✓ | Daily | 7.5% | 0.47 | -52.0% | 77.8% | 171 | -7.8% |
| 13 | MACD ✓ | Weekly | 8.0% | 0.47 | -49.6% | 52.2% | 90 | -7.4% |
| 14 | Bollinger Breakout ✓ | Weekly | 6.8% | 0.47 | -36.6% | 58.8% | 51 | -8.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For West Pharmaceutical Services (WST), RSI Trend (>50) on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.